SI1897546T1 - Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino - Google Patents

Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino

Info

Publication number
SI1897546T1
SI1897546T1 SI200031063T SI200031063T SI1897546T1 SI 1897546 T1 SI1897546 T1 SI 1897546T1 SI 200031063 T SI200031063 T SI 200031063T SI 200031063 T SI200031063 T SI 200031063T SI 1897546 T1 SI1897546 T1 SI 1897546T1
Authority
SI
Slovenia
Prior art keywords
åpyrimidin
ámethyl
dihydroxyhept
methylsulfonyl
fluorophenyl
Prior art date
Application number
SI200031063T
Other languages
English (en)
Inventor
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Astrazeneca Ab Global Ip
Univ Aberdeen Regent Walk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by Astrazeneca Ab Global Ip, Univ Aberdeen Regent Walk filed Critical Astrazeneca Ab Global Ip
Publication of SI1897546T1 publication Critical patent/SI1897546T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200031063T 1999-02-06 2000-02-01 Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino SI1897546T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
EP07008956A EP1897546B1 (en) 1999-02-06 2000-02-01 Combined compositions comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid

Publications (1)

Publication Number Publication Date
SI1897546T1 true SI1897546T1 (sl) 2011-02-28

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200030962T SI1150678T1 (sl) 1999-02-06 2000-02-01 Uporaba inhibitorjev 3-hidroksi-3-metilglutaril koencim A reduktaze za izdelavo zdravila za zdravljenje diabeticne nevropatije
SI200031063T SI1897546T1 (sl) 1999-02-06 2000-02-01 Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200030962T SI1150678T1 (sl) 1999-02-06 2000-02-01 Uporaba inhibitorjev 3-hidroksi-3-metilglutaril koencim A reduktaze za izdelavo zdravila za zdravljenje diabeticne nevropatije

Country Status (34)

Country Link
US (4) US6894058B1 (sl)
EP (2) EP1897546B1 (sl)
JP (3) JP2002536332A (sl)
KR (1) KR100699757B1 (sl)
CN (1) CN1196488C (sl)
AR (1) AR025512A1 (sl)
AT (2) ATE485823T1 (sl)
AU (1) AU763970B2 (sl)
BR (1) BR0007996A (sl)
CA (1) CA2368186C (sl)
CY (2) CY1106879T1 (sl)
CZ (2) CZ302881B6 (sl)
DE (2) DE60035575T2 (sl)
DK (2) DK1897546T3 (sl)
EE (2) EE05556B1 (sl)
ES (2) ES2286995T3 (sl)
GB (1) GB0001662D0 (sl)
HK (2) HK1041223A1 (sl)
HU (1) HU227642B1 (sl)
IL (3) IL144730A0 (sl)
IS (2) IS2793B (sl)
MX (1) MXPA01007821A (sl)
MY (1) MY138289A (sl)
NO (1) NO330400B1 (sl)
NZ (3) NZ536433A (sl)
PL (1) PL198098B1 (sl)
PT (2) PT1150678E (sl)
RU (1) RU2239456C2 (sl)
SI (2) SI1150678T1 (sl)
SK (2) SK287792B6 (sl)
TR (1) TR200102229T2 (sl)
TW (1) TWI230067B (sl)
WO (1) WO2000045818A1 (sl)
ZA (1) ZA200105885B (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
JPWO2002030425A1 (ja) * 2000-10-12 2004-02-19 日産化学工業株式会社 糖尿病合併症予防・治療剤
HUP0303497A3 (en) * 2000-10-18 2006-02-28 Pfizer Prod Inc Pharmaceutical compositions containing combination of statins and sorbitol dehydrogenase inhibitors
PL365378A1 (en) * 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
EP1618893A4 (en) * 2003-04-28 2009-08-12 Sankyo Co MEANS FOR INCREASING SUGAR CAPACITY
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
DK1643999T3 (da) * 2003-06-20 2012-01-02 Nephrogenex Inc Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
SI2326632T1 (sl) 2008-09-06 2017-11-30 Bionevia Pharmaceuticals, Inc. Nov kokristal holin epalrestata
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
NZ251741A (en) 1992-04-13 1997-06-24 Zeneca Ltd Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
AU1095695A (en) 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CN1215338A (zh) 1996-04-05 1999-04-28 武田药品工业株式会社 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
IL208330A0 (en) 2010-12-30
ES2286995T3 (es) 2007-12-16
BR0007996A (pt) 2001-10-30
JP2002536332A (ja) 2002-10-29
GB0001662D0 (en) 2000-03-15
PT1150678E (pt) 2007-09-14
IS2820B (is) 2012-12-15
HK1041223A1 (en) 2002-07-05
MY138289A (en) 2009-05-29
EP1897546A1 (en) 2008-03-12
CY1110992T1 (el) 2015-06-11
EP1150678B1 (en) 2007-07-18
SK286854B6 (sk) 2009-06-05
DE60035575D1 (de) 2007-08-30
WO2000045818A1 (en) 2000-08-10
DE60035575T2 (de) 2008-04-03
NO20013812L (no) 2001-10-02
HK1118209A1 (en) 2009-02-06
NZ513061A (en) 2003-06-30
PL198098B1 (pl) 2008-05-30
CN1338937A (zh) 2002-03-06
AU2304700A (en) 2000-08-25
EP1150678A1 (en) 2001-11-07
IS6016A (is) 2001-07-20
IL144730A (en) 2010-12-30
US20050209128A1 (en) 2005-09-22
SK11102001A3 (sk) 2002-05-09
IS2793B (is) 2012-08-15
ZA200105885B (en) 2002-10-17
DK1897546T3 (da) 2011-01-17
CZ20012806A3 (cs) 2002-02-13
NZ536433A (en) 2006-08-31
PL350312A1 (en) 2002-12-02
JP2012051898A (ja) 2012-03-15
NZ525419A (en) 2004-12-24
DE60045168D1 (de) 2010-12-09
CZ302893B6 (cs) 2012-01-11
EE05621B1 (et) 2013-02-15
CA2368186A1 (en) 2000-08-10
KR100699757B1 (ko) 2007-03-27
AU763970B2 (en) 2003-08-07
SI1150678T1 (sl) 2008-02-29
ES2352803T3 (es) 2011-02-23
IS8978A (is) 2011-08-23
CA2368186C (en) 2008-06-03
ATE485823T1 (de) 2010-11-15
JP2014065718A (ja) 2014-04-17
US20120041010A1 (en) 2012-02-16
DK1150678T3 (da) 2007-10-08
EE05556B1 (et) 2012-08-15
EE201200015A (et) 2012-10-15
ATE367162T1 (de) 2007-08-15
EE200100405A (et) 2002-10-15
US6894058B1 (en) 2005-05-17
CN1196488C (zh) 2005-04-13
HU227642B1 (en) 2011-10-28
NO330400B1 (no) 2011-04-04
HUP0105138A3 (en) 2002-11-28
RU2239456C2 (ru) 2004-11-10
SK287792B6 (sk) 2011-10-04
CY1106879T1 (el) 2012-05-23
TR200102229T2 (tr) 2001-12-21
HUP0105138A2 (hu) 2002-04-29
IL144730A0 (en) 2002-06-30
TWI230067B (en) 2005-04-01
EP1897546B1 (en) 2010-10-27
PT1897546E (pt) 2010-12-15
MXPA01007821A (es) 2004-08-19
CZ302881B6 (cs) 2012-01-04
KR20010089635A (ko) 2001-10-06
AR025512A1 (es) 2002-12-04
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
SI1897546T1 (sl) Kombinirani sestavki, ki obsegajo (E)-7-(4-(4-fluorofenil)-6-izopropil-2 -(metil(metilsulfonil)amino)pirimidin-5-il)(3r,5s)-3,5-dihidroksihept-6- enojsko kislino
SI1263739T1 (sl) Kristalinicne soli (E)-7-(4-(4-fluorofenil)-6-izopril-2- (metil(metilsulfonil)amino)pirimidin-5-il)-(3R,5S)-3,5-dihidroksihept- 6-enojske kisline
IL161942A0 (en) (+)-2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
AP1449A (en) Pharmaceutical compositions comprising a hmg reductase inhibitor.
ZA200201810B (en) Combined vaccine compositions.
HK1090361A1 (en) Crystalline form of bis (e)-7- 4-(4-fluorophenyl)-6-isopropyl-2- methyl(methylsulfonyl)amino pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoicacid calcium salt
DE60037345D1 (de) Pyrroloi2,3-d pyrimidinderivate enthaltende Zusammensetzungen
ZA200202543B (en) Bicyclic amino acid as pharmaceutical agents.
EP1144470A3 (en) Thermally stable polyetheramines
AU5009800A (en) Secure packet processor
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
AU3501400A (en) Hair care compositions comprising amino acid compounds
AU5567700A (en) Hair composition
AU2002213100A1 (en) Indole compounds as minimally physiologial function monitioring agents
AU6384100A (en) Hops acid antibacterial compositions
AU1858901A (en) Compression bone nail
AU2212397A (en) Solid hop acid salt compositions
AU2002359026A1 (en) Compositon of dentifrice
TWI347948B (en) Novel 2',5'-oligoadenylic acid compositions
AU1406001A (en) Auto-adhesive composition
AU3455000A (en) Composition for decomposing protein
AU2003257407A1 (en) S-(+)-3-{1-(2-(2,3-dihydro-1h-indol-3-yl)ethyl)-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof
AU3815600A (en) Cross-linking agent based on pyrimidine used for thermohardenable compositions
AU2003244102A1 (en) Composition against white spot disease
AU2603000A (en) Thienylbenzoylbenzazepines as vasopressin agonists